This comprehensive review summarizes the mechanism of action, pharmacokinetics, efficacy, and safety of besifloxacin ophthalmic suspension, 0.6% and examines its role in the treatment of ocular surface bacterial infections. Enhanced content To view enhanced content for this article go to
INTRODUCTION
Fluoroquinolones (FQs) have been successfully used in ophthalmology for nearly two decades, thanks in large part to a series of incremental improvements in their antimicrobial activity and pharmacokinetic profiles [1] . Today, treatment for bacterial ocular surface infections-including conjunctivitis, blepharitis, and keratitis-is largely empirical; the FQs' broad-spectrum antimicrobial activity and documented safety and lack of toxicity make them well suited to empirical therapy [2] [3] [4] . With activity against a broad spectrum of bacterial pathogens including Gram-positive, Gram-negative and anaerobic organisms [1, 5] , current-generation FQs, such as gatifloxacin, moxifloxacin, and besifloxacin, have become first-line agents for the treatment and prevention of bacterial ocular infections [6, 7] .
As with other antibiotics, resistance to FQs has developed [2, 8] . Until the early 2000s, FQ resistance was uncommon among ocular pathogens, but with the rapid increase in clinical utilization of FQs (both systemic and topical), resistance has begun to emerge [8] . Surveillance studies have shown an alarming trend of increasing resistance in ocular isolates over the past two decades [9] [10] [11] [12] [13] [14] . Most notably, pathogenic strains such as methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE) are becoming prevalent, and many strains show multidrug resistance including resistance to both earlier and current generation FQs. The first topical chlorofluoroquinolone, besifloxacin has a unique molecular structure designed to confer increased antibacterial potency [4, 17] . In susceptibility assays, besifloxacin demonstrated potent in vitro activity against a wide range of pathogens, including those that are resistant to other FQs and antibacterial classes [5] .
Perhaps the most distinctive feature of besifloxacin is its lack of a systemic formulation. Unlike all other ophthalmic FQs, besifloxacin has never been used systemically, nor has it been used in agriculture or animal husbandry [2] . Because extensive systemic antibiotic use and antibiotic use in agriculture are two major drivers of resistance development among bacteria [18] [19] [20] , it has been suggested that the limitation to ocular use may slow the development of bacterial resistance to besifloxacin, although cross-resistance from other FQs is still possible [8] .
''Besivance'' as the search terms. The search was limited to English-language articles, and 156 papers/abstracts were retrieved. Primary articles, review articles, and abstracts on the mechanism of action, pharmacokinetic properties, or clinical efficacy and safety of besifloxacin were identified (n = 52), and additional relevant articles were collected from the references of selected publications. This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors. Binding with these DNA-tethered enzymes to form FQ-enzyme-DNA complexes, the FQs exert their effect by inhibiting the topoisomerases, blocking DNA replication, and, ultimately, killing the bacterial cell [6, 22] .
RESULTS AND DISCUSSION

Mechanism of Action
Older FQs, such as ofloxacin and ciprofloxacin, preferentially bind one of the essential enzymes [6] . In most Gram-negative bacteria, topoisomerase II tends to be the primary target; in Gram-positive organisms, the primary target is typically topoisomerase IV [6, 23] . However, newer agents, such as gatifloxacin and moxifloxacin, are believed to possess dual activity, with more comparable targeting activity against both topoisomerases [6, 24] . This dual-binding mechanism of action increases antimicrobial activity, particularly activity against Gram-positive pathogens [6] (Table 1) .
Maximum mean besifloxacin concentration in the tear fluid was 610 lg/g at 10 min after a single topical administration. Tear concentrations of 10 lg/g and higher were sustained through 12 h and 1.60 lg/g and higher through 24 h, well above the MIC 90 for major ocular pathogens, such as S. pneumoniae, S. aureus, S. epidermidis, and H. influenzae [5] . The elimination half-life of besifloxacin in human tears was estimated to be 3.4 h.
The commercially available besifloxacin 0.6% ophthalmic suspension is formulated with a mucoadhesive polymer (DuraSite Ò , InSite Vision Inc., Alameda, CA, USA) that enhances drug retention on the ocular surface [46] . [47] . By comparison, the AUC 0-24 /MIC 90 
Bacterial Conjunctivitis
Acute bacterial conjunctivitis is normally a self-limiting condition, but topical antibiotic therapy can speed clinical and microbiological resolution, reduce the severity of the infection, and lower the risk of complications such as keratitis [54, 55] . Table 2 ). The most commonly isolated bacterial species in this study were H. influenzae (31.7%), S. pneumoniae (27.6%), S. aureus (13.8%), and S. epidermidis (4.8%). Besifloxacin showed high rates of eradication of each of these species at day 4 ± 1, in agreement with its low MIC 90 (0.06-0.25 lg/mL) against these pathogens.
Tepedino et al. [57] reported similar efficacy results from a vehicle-controlled phase III study that enrolled 957 patients with acute bacterial 
Bacterial Keratitis
The clinical efficacy of besifloxacin 0.6% in the treatment of bacterial keratitis has not been evaluated in randomized, controlled studies. Michaud reported a case of a patient with contact lens-related severe keratitis that was successfully treated with a regimen that included besifloxacin 0.6% [67] . Pandit [68] described a case of a patient with a large corneal ulcer due to Brevundimonas diminuta. [70, 71] . Besifloxacin has also been found more effective (P\0.05) than gatifloxacin and moxifloxacin in reducing bacterial loads in rabbit corneas infected with a resistant strain of P. aeruginosa [72] .
Antibacterial Prophylaxis for Surgery
No topical antibiotic is currently approved for prophylactic use in ocular surgery. Given the low rate of postoperative endophthalmitis [73, 74] , prospective studies of topical antibiotic prophylaxis would require extremely large study populations. Nevertheless, use of topical antibiotics-particularly fourth-generation FQs-as surgical prophylaxis is considered a standard of care [75, 76] . Retrospective studies suggest that perioperative use of fourth-generation FQs such as moxifloxacin or gatifloxacin is associated with low rates of endophthalmitis after cataract surgery [76, 77] . Human and animal data from previously mentioned pharmacokinetic studies suggests that intraocular penetration of FQs, in general, is minimal [49, [51] [52] [53] . Since topical administration of current FQs cannot achieve high aqueous humor drug concentrations, an appropriate goal for topical antibiotics in surgical prophylaxis is the reduction of the number of pathogens on the ocular surface.
Indeed, the normal microflora on the eyelids and conjunctival sac is the main source of the bacteria associated with endophthalmitis, the predominant causative organisms being Gram-positive species, most commonly CoNS (S. epidermidis) [78, 79] .
Bucci et al. [80] (Table 3) , with rare nonocular side effects [59, 89] . Most adverse events in these studies were mild or moderate in severity.
In addition, besifloxacin was well-tolerated by the pediatric patients in the besifloxacin clinical trials dosed three times daily for 5 days (N = 815), with similarly low incidences of ocular adverse events found in all treatment groups (besifloxacin, moxifloxacin, and vehicle)
[61]. The most commonly reported adverse events in besifloxacin-treated eyes from pediatric patients were conjunctivitis (2.9%), bacterial conjunctivitis (2.1%), and eye pain in patients undergoing LASIK surgery was not associated with any adverse drug reaction [83] .
Similarly, a recent prospective, multisite, LASIK safety surveillance study by Majmudar and
Clinch [85] suggested besifloxacin appears safe for surgical prophylaxis; among the 456 study eyes (besifloxacin: n = 344; moxifloxacin, n = 112), no treatment-emergent adverse events were reported.
However, problems with the prophylactic use of besifloxacin in the surgical setting have been reported under particular circumstances.
Talamo et al. [91] reported delayed epithelial closure (5 to 13 days, with an average of 8.8 days) and delayed visual recovery in a case series of 4 patients (7 eyes) treated with besifloxacin 0.6% instilled underneath a bandage contact lens (BCL) placed at the conclusion of photorefractive keratectomy (PRK) [91] . These adverse reactions were attributed by the authors to potential toxic effects of DuraSite or the preservative benzalkonium chloride 0.01% on exposed during LASIK or PRK while the stromal bed is exposed [92] .
To date, there has been no other evidence in the literature for such adverse events with the besifloxacin formulation. Donnenfeld et al. [84] evaluated the effect of besifloxacin 0.6% or moxifloxacin 0.5% (Vigamox) on epithelial wound healing following PRK in a prospective, contralateral eye, double-masked, multicenter study. A total of 80 eyes (40 patients) were randomized to either besifloxacin or moxifloxacin administered 3 times daily after [93, 94] .
Concerns have also emerged in regards to suture-less clear corneal surgery, where it has been suggested that a leaking wound could give the DuraSite vehicle entry to the anterior chamber, block the trabecular meshwork, and cause significant anterior chamber toxicity [95, 96] . Studies in patients undergoing routine, uncomplicated, suture-less cataract surgery, however, have thus far produced no clinical evidence that prophylactic use of besifloxacin is associated with any significant safety concerns.
A randomized, parallel-group, investigator-masked study of 58 patients undergoing suture-less clear cornea surgery reported no adverse events with either besifloxacin or moxifloxacin used prophylactically (both administered 4 times daily starting 3 days prior to surgery and continued for 7 days postoperatively) [81] .
Similarly, Parekh et al. [82] found no evidence of adverse drug reactions following besifloxacin or moxifloxacin prophylaxis in a retrospective chart review of more than 700 consecutive cases of routine cataract surgery obtained from nine clinical centers in the US (besifloxacin: n = 493, 89% suture-less; moxifloxacin: n = 253, 78%
suture-less) [82] . Finally, in a prospective, multisite, cataract surgery surveillance study of 485 eyes (besifloxacin: n = 333; moxifloxacin: 61. Comstock TL, Paterno MR, Usner DW, Pichichero ME. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked,
